Researchers find clue to Parkinson’s gene therapy
An enzyme that clears out alpha-synuclein from neurons may counteract Parkinsons Disease, report researchers from ETH Zürich and Novartis.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1997 entries already.
Entries by Thomas Gabrielczyk
Chikungunya vaccine developer Themis bags $21m
Under a partnering ageement with CEPI, Themis Bioscience will receive $21m to push pivotal testing of MV-CHIK, its Chikungunya vaccine candidate.
Genetically modified fungus stops malaria mosquitoes
A fungus that produces an insecticide can stop the spread of Anopheles mosquito, which causes malaria.
Abacus Medicine postpones IPO
European pharmaceutical parallel trade company Abacus Medicine A/S has postponed its planned Initial Public Offering (IPO), due to "unfavourable market environment".
Make leukaemia therapy safer
A Belgian-British-Australian research team has created a safer version of a therapy that combats the aggressive form of a blood cancer called acute lymphoblastic leukemia (ALL) while avoiding toxicity.
Nanobiotix spins out Curadigm
Cancer-focussed Nanobiotix SA has spun out Curadigm, which offers a platform to improve the bioavailability of nanomedicines by reducing liver and spleen toxicity and accumulation.
Most expensive gene therapy globally approved
The FDA has approved Novartis-subsidiary AveXis Inc’s spinal muscular atrophy (SMA) gene therapy Zolgensma (onasemnogene abeparvovec-xioi). The company wants to set the price tag at $2,125m per dose.
Chiesi acquires ex-US Raxone marketing rights
Chiesi Farmaceutici has licenced commercialiation rights for LHON treatment Raxone (idebenone) from Santhera Pharmaceuticals for CHF50m (€44m) in cash plus sales milestones.
EU ministers set to exclude CRISPR crops from GMO legislation
EU agriculture ministers want to exclude crops created by targeted mutation methods from EU GMO legislation.
Evotec acquires CDMO Just Biotherapeutics in US$90m deal
Evotec SE is set to acquire biologics manufacturing specialist Just Biotherapeutics, Inc in a deal that could amount up to $90m.